CBIO Q2 2025 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$345M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$2,000

Operating Income

-$21M

Net Income

-$22M

EPS (Diluted)

$-0.28

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$157M

Total Liabilities

$18M

Stockholders' Equity

$139M

Cash & Equivalents

$153M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$2,000	-$12,423	+83.9%
Operating Income	-$21M	-$10M	-103.0%
Net Income	-$22M	-$10M	-115.8%

Revenue Segments

Reportable Segment

$3M100%